Test formulation D3

Test formulation D3 is an experimental oral formulation of celecoxib designed for enhanced bioavailability. Developed by Pfizer's Upjohn division (which merged with Mylan to form Viatris), this formulation aims to provide more favorable pharmacokinetic characteristics compared to the standard commercial formulation of Celebrex. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor, a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation. By specifically targeting COX-2, it inhibits the synthesis of pro-inflammatory prostaglandins while sparing the COX-1 isoenzyme, which is associated with gastrointestinal protection. The D3 formulation was evaluated in a Phase 1 crossover study at a 150 mg dose to compare its bioavailability against the 200 mg commercial Celebrex capsule in healthy volunteers, targeting indications such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute pain.

Other names

Enhanced Bioavailability Celecoxib Formulation D3